The New Gilead Is Shaping Up [Seeking Alpha]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Seeking Alpha
Summary Prospective Gilead growth drivers from 2017 are still just "prospective Gilead growth drivers", save one. Gilead's bold foray into immunotherapy has so far netted it an FDA approval, a BLA, a pipeline and a dynamic role in one of tomorrow's great technologies. Gilead's expansion into China remains very much a work in progress, likely a long range project. Gilead's key non-HIV, non-HCV molecules from 2017, filgotinib and selonsertib, have advanced in opposite directions. Gilead's near-term revenue generators are counteracted by its decliners. After penning dozens of optimistic Gilead (NASDAQ: GILD Review of a competing gene therapy company for a possible article rekindled enough interest in its competitor Gilead for me to check out Gilead's most recent earnings CC. I was intrigued by what I found; I switched my article project to this current effort. My string of optimistic Gilead articles ran from March 2016's " Gilead's Harvoni: A Fair Deal Gilead's 2018 And Beyond - Buckle U
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Australian community organisations addressing viral hepatitis receive AU$400,000 via global Gilead ALL4LIVER Grant programPR Web
- Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know [Yahoo! Finance]Yahoo! Finance
- US FDA mandates label updates on CAR-T cancer therapies [Yahoo! Finance]Yahoo! Finance
- Global CAR T-Cell Therapy Market Size To Worth USD 21.92 Billion By 2033 | CAGR of 17.72% [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences Publishes 2023 ESG Impact Report [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/6/24 - Miss
GILD
Sec Filings
- 4/2/24 - Form 4
- 4/1/24 - Form 144
- 3/29/24 - Form 4
- GILD's page on the SEC website